B. Betts

D. Couriel, K. MacDonald, B. Betts, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Emerging Therapeutics for the Control of Chronic Graft-versus-Host Disease.

D. Couriel, K. MacDonald, B. Betts, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Current Concepts and Advances in Graft-Versus-Host Disease Immunology.

G. Hill, B. Blazar, V. Tkachev, 2021, Annual review of immunology.

Effect of Keratinocyte Growth Factor on Hospital Readmission and Regimen-Related Toxicities after Autologous Hematopoietic Cell Transplantation for Lymphoma.

D. Weisdorf, M. Arora, A. Rashidi, 2021, Transplantation and cellular therapy.

Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK1/2 Blockade

K. Hsu, G. Heller, James W. Young, 2016, Cancer Immunology Research.

Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK 1 / 2 Blockade Running Title : DCs mitigate NK dysfunction from JAK 1 / 2 inhibition

K. Hsu, J. Chung, G. Heller, 2016 .

Dual JAK2/Aurora kinase A inhibition prevents human skin graft rejection by allo‐inactivation and ILC2‐mediated tissue repair

J. Tolar, S. Sebti, J. Pidala, 2021, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Hepatic veno-occlusive disease following sirolimus-based immune suppression

J. Pidala, C. Anasetti, F. Locke, 2018, Bone Marrow Transplantation.

A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease

J. Pidala, A. Mishra, Jongphil Kim, 2021, Blood advances.

STAT5 polarization promotes iTregs and suppresses human T‐cell alloresponses while preserving CTL capacity

J. Pidala, C. Anasetti, Xue-Zhong Yu, 2014, Journal of leukocyte biology.

Human herpesvirus 6 infection after hematopoietic cell transplantation: is routine surveillance necessary?

D. Weisdorf, C. Ustun, Jo-Anne H. Young, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Less Can Be More When Targeting Interleukin-6-Mediated Cytokine Release Syndrome in Coronavirus Disease 2019

James W. Young, B. Betts, 2020, Critical care explorations.

Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation

J. Singer, J. Pidala, C. Anasetti, 2018, Proceedings of the National Academy of Sciences.

The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality

J. Perkins, J. Pidala, Jongphil Kim, 2011, Haematologica.

Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory Study.

J. Pidala, C. Anasetti, F. Locke, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T Cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma

David M. Woods, A. Laino, D. Woods, 2018, Clinical Cancer Research.

Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-tumor Immunity

J. Pidala, J. D. Del Valle, C. Hu, 2018, Front. Immunol..

Sirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic cell transplantation: a single institution experience

J. Perkins, J. Pidala, A. Mishra, 2015, Bone Marrow Transplantation.

A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation

H. Jim, J. Perkins, J. Pidala, 2012, Haematologica.

Association of CD34 cell dose with 5-year overall survival after peripheral blood allogeneic hematopoietic cell transplantation in adults with hematologic malignancies.

M. Arora, V. Bachanova, Q. Cao, 2021, Transplantation and cellular therapy.

Hemophagocytic lymphohistiocytosis induced by Toxoplasma gondii infection diagnosed by a bone marrow biopsy and DNA next‐generation sequencing in an allogeneic hematopoietic stem cell transplant recipient

S. Arbefeville, P. Ferrieri, A. Slungaard, 2021, Transplant infectious disease : an official journal of the Transplantation Society.

Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission

J. Perkins, J. Pidala, C. Anasetti, 2014, Bone Marrow Transplantation.

SOLE UPFRONT THERAPY WITH BECLOMETHASONE AND BUDESONIDE FOR UPPER GASTRO-INTESTINAL ACUTE GVHD: Topical therapy for upper gastrointestinal GVHD.

J. Pidala, A. Mishra, Jongphil Kim, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Sole Upfront Therapy with Beclomethasone and Budesonide for Upper Gastrointestinal Acute Graft-versus-Host Disease

J. Pidala, A. Mishra, Jongphil Kim, 2020 .

Stress responses , M 2 macrophages , and a distinct microbial signature in fatal intestinal acute graft-versus-host disease

A. Khoruts, M. MacMillan, D. Weisdorf, 2019 .

Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results.

J. Pidala, A. Mishra, Jongphil Kim, 2015, Biology of Blood and Marrow Transplantation.

The IL-12 Cytokine and Receptor Family in Graft-vs.-Host Disease

D. Bastian, Yongxia Wu, Xue-Zhong Yu, 2019, Front. Immunol..

Tolerance Associated Gene Expression following Allogeneic Hematopoietic Cell Transplantation

S. Eschrich, M. Sarwal, G. Bloom, 2012, PloS one.

Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease

H. Jim, J. Pidala, A. Mishra, 2015, Haematologica.

Phase I trial of histone deacetylase inhibitor panobinostat in addition to glucocorticoids for primary therapy of acute graft-versus-host disease

J. Pidala, A. Mishra, C. Anasetti, 2018, Bone Marrow Transplantation.

Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results

S. Sebti, J. Pidala, A. Mishra, 2021, Clinical Cancer Research.

A phase 2 trial of the histone deacetylase inhibitor panobinostat for graft-versus-host disease prevention.

J. Pidala, A. Mishra, Xuefeng Wang, 2021, Blood advances.

High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group

S. Bhatia, G. Vercellotti, M. MacMillan, 2021, Blood Cancer Journal.

Hypoalbuminaemia segregates different prognostic subgroups within the refined standard risk acute graft‐versus‐host disease score

J. Pidala, C. Anasetti, J. Chavez, 2018, British journal of haematology.

In vivo IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation

H. Jim, J. Pidala, A. Mishra, 2017, Haematologica.

High cutaneous amphiregulin expression predicts fatal acute graft‐versus‐host disease

M. MacMillan, D. Weisdorf, B. Blazar, 2022, Journal of cutaneous pathology.

Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention

J. Pidala, A. Mishra, C. Anasetti, 2017, Bone Marrow Transplantation.

Outcomes of chronic graft-versus-host disease following matched sibling donor versus umbilical cord blood transplant

J. Wagner, M. MacMillan, D. Weisdorf, 2021, Bone Marrow Transplantation.

Tregs served sunny-side up.

James W. Young, B. Betts, 2010, Blood.

Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia

J. Perkins, J. Pidala, A. Mishra, 2020, Leukemia & lymphoma.

Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization

M. Schell, J. Perkins, J. Pidala, 2013, Bone Marrow Transplantation.

Prophylactic foscarnet for human herpesvirus 6: effect on hematopoietic engraftment after reduced intensity conditioning umbilical cord blood transplantation.

J. Wagner, D. Weisdorf, M. Arora, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Sirolimus/Tacrolimus Facilitates Preferential Recovery of Regulatory T Cells (Treg) After Allogeneic Hematopoietic Cell Transplantation (HCT), and Is More Effective Than Methotrexate/Tacrolimus in Preventing Grade II-IV Acute Graft Vs. Host Disease (GVHD) and Moderate to Severe Chronic Gvhd

H. Jim, J. Perkins, J. Pidala, 2011 .

Objective and subjective physical function in allogeneic hematopoietic stem cell transplant recipients

H. Jim, J. Pidala, A. Mishra, 2021, Bone Marrow Transplantation.

Facilitating resolution of life-threatening acute GVHD with human chorionic gonadotropin and epidermal growth factor.

J. Wagner, Chi Chen, G. Vercellotti, 2020, Blood advances.

Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in GVHD Risk Without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate

C. Ebens, S. Terezakis, V. Bachanova, 2022, medRxiv.

Sarcopenia Predicts Inferior Progression Free Survival in Lymphoma Patients Treated with Autologous Hematopoietic Stem Cell Transplantation.

R. Assi, Q. Cao, S. Holtan, 2022, Transplantation and cellular therapy.

Clarifying the translational potential of B-I09

Juan R. Del Valle, Brian C. Betts, Xue-Zhong Yu, 2020, Nature Chemical Biology.

New sources for argument: do HLA-C and HLA disparity in adult double umbilical cord blood transplants predict outcomes?

J. Pidala, C. Anasetti, H. Fernandez, 2016, Bone Marrow Transplantation.

Phase II, Open-Label Clinical Trial of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor for Life-Threatening Acute Graft-Versus-Host Disease.

M. MacMillan, D. Weisdorf, B. Blazar, 2023, Transplantation and cellular therapy.

Phase II Study of Myeloablative 7-8/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil.

C. Ebens, G. Vercellotti, Jeffrey S. Miller, 2023, Transplantation and cellular therapy.

Pre‐transplant and longitudinal changes in faecal microbiome characteristics are associated with subsequent development of chronic graft‐versus‐host disease

Benjamin M Hillmann, Robin R. Shields-Cutler, A. Khoruts, 2023, British journal of haematology.

Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results.

J. Pidala, A. Mishra, Jongphil Kim, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease

J. Pidala, A. Mishra, Jongphil Kim, 2022 .

Human Langerhans cells use an IL-15R-α/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1.

G. Altan-Bonnet, G. Heller, James W. Young, 2012, Blood.

Human regulatory T cells against minor histocompatibility antigens: ex vivo expansion for prevention of graft-versus-host disease.

W. Janssen, J. Pidala, Jongphil Kim, 2013, Blood.

JAK-STAT inhibition reduces endothelial prothrombotic activation and leukocyte–endothelial proadhesive interactions

D. K. Wood, G. Vercellotti, E. Aronovich, 2023, Journal of thrombosis and haemostasis : JTH.